Michael Pickrell, MD
Rheumatology · Oklahoma City, OKNPI 1346253325
Payments from drug & device makers
Across 641 payments — averaging $254.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$109K
- GSK$44K
- AbbVie$2K
- UCB, Inc.$1K
- Amgen$1K
- AstraZeneca$1K
- plus $5K from 18 others
Across 9 payments — averaging $89.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$802
What the payments were for
- Food & beverage$9,70397%
- Education$3503%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 23 | $109,174 |
| GSK | 24 | $44,372 |
| AbbVie | 111 | $1,538 |
| UCB, Inc. | 66 | $1,381 |
| Amgen(2 entities) | 80 | $1,121 |
| AstraZeneca(2 entities) | 50 | $1,069 |
| Johnson & Johnson | 52 | $1,028 |
| E.r. Squibb & Sons, L.L.C. | 56 | $784 |
| Novartis | 35 | $575 |
| Lilly USA, LLC | 28 | $534 |
| Radius Health, Inc. | 18 | $388 |
| Pfizer | 48 | $353 |
| Genentech USA, Inc. | 11 | $209 |
| Fresenius Kabi USA, LLC | 10 | $188 |
| Sandoz | 8 | $173 |
| Boehringer Ingelheim | 5 | $110 |
| Sanofi | 4 | $103 |
| Janssen Scientific Affairs, LLC | 3 | $79 |
| Aurinia Pharma U.S., Inc. | 3 | $59 |
| Mallinckrodt Hospital Products Inc. | 1 | $39 |
| Organon | 2 | $37 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| Tonix Medicines, Inc. | 1 | $14 |
| Bristol Myers Squibb | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAPHNELO$105
How this compares
$163,357 in reported general payments places this provider in the 85th percentile of 67 rheumatology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 56 | $566,552 |
| Humira(Cf) PenAdalimumab | 40 | $280,528 |
| RinvoqUpadacitinib | 45 | $278,360 |
| EnbrelEtanercept | 35 | $255,226 |
| Orencia ClickjectAbatacept | 36 | $201,892 |
| Cosentyx Sensoready PenSecukinumab | 27 | $192,768 |
| OrenciaAbatacept | 19 | $108,254 |
| ForteoTeriparatide | 18 | $74,472 |
| XeljanzTofacitinib Citrate | 12 | $69,415 |
| KineretAnakinra | 12 | $66,490 |
| BenlystaBelimumab | 12 | $58,396 |
| KevzaraSarilumab | 12 | $51,075 |
| Hydroxychloroquine Sulfate | 316 | $11,371 |
| MethotrexateMethotrexate Sodium | 337 | $11,298 |
| Pilocarpine Hcl | 59 | $5,063 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $1,538 | $278,36045 claims |
| AmgenEnbrel | $1,121 | $255,22635 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $784 | $108,25419 claims |
| Lilly USA, LLCForteo | $534 | $74,47218 claims |
| PfizerXeljanz | $353 | $69,41512 claims |
| GSKBenlysta | $44,372 | $58,39612 claims |
| SanofiKevzara | $103 | $51,07512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 67 rheumatology providers in Oklahoma.
Other rheumatology in Oklahoma City
- Christine CoddingOklahoma City$2.8M
- Latisha HeinlenOklahoma City$1.9M
- Cristina ArriensOklahoma City$1.8M
- Joan MerrillOklahoma City$1.8M
- Mohammad KhanOklahoma City$999K
- Fahed HamadehOklahoma City$321K
- William SchnitzOklahoma City$290K
- John GoetzingerOklahoma City$38K
- Judith JamesOklahoma City$18K
- Robert ArthurOklahoma City$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.